At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christoph Röllig, MD, from…
Browsing: Acute Lymphoblastic Leukemia
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from…
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from…
Immunotherapy is personalized therapy for people with cancer–but can it outsmart CLL? Experts Drs. John Gribben, Constantine Tam,and William Wierda,…
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from…
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial…
Tony Choueiri, MD of Dana Farber discusses CheckMate 025 phase III trial at ASCO GU 2016
Robert Dreicer, MD of the University of Virginia Health System discusses immunotherapy in non muscle invasive bladder cancer at ASCO…
Robert Dreicer, MD of the University of Virginia Health System discusses the how soon should we expect approval of immunotherapy…
Robert Dreicer, MD of the University of Virginia Health System discusses the future role of immunotherapy and checkpoint inhibitors in…
Robert Dreicer, MD of the University of Virginia Health System discusses how Atezolizumab shows very significant activity in advanced urothelial…
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter…
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD,…
Monoclonal antibodies have been recognised for their significant potential in the treatment of multiple myeloma. At the German Cancer Congress…
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Dirk Reinhardt, MD, PhD,…
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from…
Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease. At the German Cancer Congress 2016, held in Berlin, Germany, from…
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from…
Progress in the field of blood cancers has resulted in the rapid development of more effective, less toxic therapies. At…
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from…
At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Axel Hauschild, MD,…
What are monoclonal antibodies, and how are they used to treat CLL? From MD Anderson Cancer Center, Drs. Zeev Estrov…
Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole…
Are you refractory to some of the existing myeloma medications? Are you a relapsed patient? Myeloma experts Drs. John Burke,…
Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole…
Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in…
Dr. Petros Grivas, MD at Cleveland Clinic discusses how genomics in urothelial carcinomas may play much bigger role in the…
Dr. Petros Grivas, MD at Cleveland Clinic discusses inhibiting autophagy in bladder cancer at ASCO GU 2016
Dr. Petros Grivas, MD at Cleveland Clinic discusses clinical and pathological factors that can influence outcomes in upper tract urothelial…
Dr. Petros Grivas, MD at Cleveland Clinic discusses if treatment for prior cancer develops secondary bladder cancer at ASCO GU…
Marin Xavier, MD of the Scripps Health discusses the greatest impact of immune checkpoint inhibitors in hematologic malignancies at Scripps…
Marin Xavier, MD of the Scripps Health discusses the management of hematologic and solid tumor malignancies with PD-1 and PD-L1…
Marin Xavier, MD of the Scripps Health discusses the most common adverse events for PD-1 and PD-L1 monoclonal antibodies at…
Marin Xavier, MD of the Scripps Heal;th discusses her real world experience with the novel immune checkpoint inhibitors at Scripps…
At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Axel Hauschild, MD,…
Josep-Maria Ribera, MD, PhD from the Germans Trias i Pujol University Hospital, Barcelona, Spain, presents preliminary data, which shows that…
Tanguy Seiwert, MD of the University of Chicago discusses using biomarkers in Immunotherapy in Head and Neck Cancer at Scripps…
Tanguy Seiwert, MD of the University of Chicago discusses Pembrolizumab and nivolumab Immunotherapies and that they Show Efficacy in Head…
Tanguy Seiwert, MD of the University of Chicago discusses Immunotherapy and how it is well tolerated in Head and Neck…
Tanguy Seiwert, MD of the University of Chicago discusses immunotherapy and future use of combination treatment in Head and Neck…
Susan M. O’Brien, MD of University of California Irvine discusses Venetoclax in the management of CLL and where in the…
Susan M. O’Brien , MD of University of California Irvine the preferred treatment regimen for patients who fail frontline therapy…
Susan M. O’Brien, MD of University of California Irvine the preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab at Scripps Health…
Susan M. O’Brien, MD of University of California Irvine discusses the preferred frontline regimen for new CLL patients greater than…
Susan M. O’Brien, MD of University of California Irvine discusses how to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting…
Susan M. O’Brien, MD of University of California Irvine discusses FCR produces better and longer progression free survival than BR…
Susan M. O’Brien, MD of University of California Irvine discusses Duvelisib and other PI3K inhibitors in CLL at Scripps Health…
Susan M. O’Brien, MD of University of California Irvine discusses Acalabrutinib, ONO-4059 and other novel BTK inhibitors in CLL at…
Omid Hamid, MD of The Angeles Clinic discusses the future of Immunotherapy new developments and new clinical trials at Scripps…
Omid Hamid, MD of The Angeles Clinic discusses how important it is in Immunotherapy to find the correct biomarkers at…